Clinical trial
A Randomized, Double-Blind, Placebo-controlled, Ascending, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Mild Atopic Asthma
NCT01928368 is registered in ClinicalTrials.gov with Amgen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-controlled, Ascending, Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Mild Atopic Asthma
- Lead sponsor
- Amgen
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 31, 2013
- Completion date
- March 31, 2016
- Enrollment
- 70 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.